UY32359A - Compuestos de plasmalogenos, composiciones farmaceuticas que los contienen y metodos para tratar enfermedades del envejecimiento - Google Patents

Compuestos de plasmalogenos, composiciones farmaceuticas que los contienen y metodos para tratar enfermedades del envejecimiento

Info

Publication number
UY32359A
UY32359A UY0001032359A UY32359A UY32359A UY 32359 A UY32359 A UY 32359A UY 0001032359 A UY0001032359 A UY 0001032359A UY 32359 A UY32359 A UY 32359A UY 32359 A UY32359 A UY 32359A
Authority
UY
Uruguay
Prior art keywords
compounds
pharmaceutical compositions
compositions containing
plasmalogen
methods
Prior art date
Application number
UY0001032359A
Other languages
English (en)
Inventor
Khan M Amin
Paul L Wood
Dayan Goodenowe
Rishikesh Mankidy
Pearson Ahiahonu
Original Assignee
Phenomenome Discoveries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phenomenome Discoveries Inc filed Critical Phenomenome Discoveries Inc
Publication of UY32359A publication Critical patent/UY32359A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02—Five-membered rings
    • C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • C07F9/106—Adducts, complexes, salts of phosphatides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Derivados de 1-alquilo-2-acilglicerol útiles en el tratamiento o prevención de enfermedades neurodegenerativas, cáncer, osteoporosis y enfermedades vasculares, composiciones farmacéuticas que las contienen y equipos que incorporan dichos compuestos.
UY0001032359A 2008-12-22 2009-12-22 Compuestos de plasmalogenos, composiciones farmaceuticas que los contienen y metodos para tratar enfermedades del envejecimiento UY32359A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13969508P 2008-12-22 2008-12-22

Publications (1)

Publication Number Publication Date
UY32359A true UY32359A (es) 2010-05-31

Family

ID=42286823

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032359A UY32359A (es) 2008-12-22 2009-12-22 Compuestos de plasmalogenos, composiciones farmaceuticas que los contienen y metodos para tratar enfermedades del envejecimiento

Country Status (17)

Country Link
US (1) US9334235B2 (es)
EP (1) EP2382201B1 (es)
JP (2) JP5740312B2 (es)
KR (1) KR101810988B1 (es)
CN (2) CN105859680A (es)
AR (2) AR074854A1 (es)
AU (1) AU2009329784B2 (es)
BR (1) BRPI0922619A8 (es)
CA (1) CA2746831C (es)
IL (1) IL213409A0 (es)
MX (1) MX350291B (es)
MY (1) MY169797A (es)
RU (1) RU2546108C2 (es)
SG (1) SG172340A1 (es)
TW (1) TWI475989B (es)
UY (1) UY32359A (es)
WO (1) WO2010071988A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102413822A (zh) * 2009-03-04 2012-04-11 雀巢产品技术援助有限公司 提高哺乳动物中内源性缩醛磷脂水平的方法
SG179122A1 (en) 2009-10-01 2012-05-30 Phenomenome Discoveries Inc Serum-based biomarkers of pancreatic cancer and uses thereof for disease detection and diagnosis
JP5934483B2 (ja) * 2011-09-05 2016-06-15 学校法人帝京大学 リン脂質結合型ｄｈａ増加剤
JP5997887B2 (ja) * 2011-09-05 2016-09-28 学校法人帝京大学 経口投与剤
WO2015064960A1 (ko) 2013-10-29 2015-05-07 울산대학교 산학협력단 플라스마로젠 전구체, 플라스마로젠 또는 플라스마로젠 유사체를 유효성분으로 함유하는 간질환 예방 또는 치료용 약학조성물
WO2016041013A1 (en) * 2014-09-16 2016-03-24 Baker Idi Heart And Diabetes Institute Holdings Limited Glycerolipids and uses therefor
CN108276438B (zh) * 2018-02-02 2020-05-22 中国海洋大学 一种epa缩醛磷脂的制备方法及其应用
CN112166116B (zh) 2018-04-27 2024-04-12 株式会社流变机能食品研究所 新型缩醛磷脂衍生物
WO2020009173A1 (ja) * 2018-07-06 2020-01-09 丸大食品株式会社 プラズマローゲン含有組成物
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
CN112321446A (zh) * 2020-11-25 2021-02-05 华南理工大学 一种酰胺衍生物的合成方法
CN113150270A (zh) * 2021-03-19 2021-07-23 广东丁沃生医疗器械有限公司 一种磷脂聚合物及其制备方法与应用
WO2023027021A1 (ja) * 2021-08-23 2023-03-02 株式会社レオロジー機能食品研究所 新規プラズマローゲン誘導体
CN118284615A (zh) 2021-11-22 2024-07-02 株式会社食物流变功能研究所 化合物、其外消旋体、它们的盐、组合物、抗炎剂、痴呆症治疗剂及雷特综合征治疗剂
WO2024111529A1 (ja) * 2022-11-21 2024-05-30 株式会社 レオロジー機能食品研究所 脳プラズマローゲン増加剤、脳プラズマローゲン増加用経口組成物及び化合物の使用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4827011A (en) * 1984-12-10 1989-05-02 American Cyanamid Company Antihypertensive phosphate derivatives
FR2736265B1 (fr) 1995-07-07 1997-09-26 Forgeot Marcel Nouvelles compositions a base de phosphoglycero ethers et leur utilisation dans le traitement des maladies neuro-degeneratives
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
US6838452B2 (en) 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
JP2004026803A (ja) 2002-03-29 2004-01-29 Nof Corp 神経細胞死予防剤
US20080020472A1 (en) 2005-11-22 2008-01-24 Frantz Biomarkers, Llc Method for detecting an inflammatory disease or cancer
CA2689848A1 (en) 2006-02-28 2007-09-07 Phenomenome Discoveries Inc. Methods for the diagnosis of dementia and other neurological disorders
US20080021000A1 (en) 2006-07-19 2008-01-24 Su Chen Mixtures of and methods of use for polyunsaturated fatty acid-containing phospholipids and alkyl ether phospholipids species
JP2008125365A (ja) * 2006-11-16 2008-06-05 Kagoshima Univ 高純度プラスマローゲン調製法
JPWO2008093709A1 (ja) * 2007-01-30 2010-05-20 株式会社プロジェクト・エム アミロイド蛋白質の凝集抑制および分解促進によりアミロイドーシスと関連する疾患を予防または治療するための組成物
AU2007346587C1 (en) 2007-02-08 2015-01-22 Med-Life Discoveries Lp Methods for the treatment of Senile Dementia of the Alzheimer's Type
CA2680748C (en) 2007-04-13 2012-08-28 Phenomenome Discoveries Inc. Methods for the diagnosis and risk assessment of plasmalogen deficiency mediated diseases of aging

Also Published As

Publication number Publication date
CN102369193A (zh) 2012-03-07
AR074854A1 (es) 2011-02-16
MY169797A (en) 2019-05-15
WO2010071988A1 (en) 2010-07-01
JP5740312B2 (ja) 2015-06-24
IL213409A0 (en) 2011-07-31
EP2382201B1 (en) 2022-08-24
MX2011006795A (es) 2011-09-26
US9334235B2 (en) 2016-05-10
SG172340A1 (en) 2011-07-28
JP2015145388A (ja) 2015-08-13
BRPI0922619A8 (pt) 2023-01-10
BRPI0922619A2 (pt) 2016-09-13
TWI475989B (zh) 2015-03-11
KR20110104002A (ko) 2011-09-21
AR117572A2 (es) 2021-08-18
KR101810988B1 (ko) 2017-12-20
AU2009329784A1 (en) 2011-07-07
US20130116312A2 (en) 2013-05-09
RU2011124579A (ru) 2013-01-27
CN102369193B (zh) 2016-05-04
CA2746831A1 (en) 2010-07-01
EP2382201A1 (en) 2011-11-02
WO2010071988A8 (en) 2011-07-21
AU2009329784B2 (en) 2016-08-25
RU2546108C2 (ru) 2015-04-10
JP2012512816A (ja) 2012-06-07
EP2382201A4 (en) 2015-11-18
CA2746831C (en) 2013-11-26
MX350291B (es) 2017-09-04
CN105859680A (zh) 2016-08-17
TW201034662A (en) 2010-10-01
US20120035250A1 (en) 2012-02-09

Similar Documents

Publication Publication Date Title
UY32359A (es) Compuestos de plasmalogenos, composiciones farmaceuticas que los contienen y metodos para tratar enfermedades del envejecimiento
CO2020007218A2 (es) Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
UY30220A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
DOP2012000257A (es) Derivados del acido 1-amino-2-ciclopropiletilboronico
MX2020010535A (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
PH12015500825B1 (en) Substituted benzene compounds
PE20151023A1 (es) Triazolopirazinas
ECSP14017269A (es) Compuestos para tratar la atrofia muscular espinal
CL2012003226A1 (es) Compuestos derivados de 5-fluoro-1h-pirazolopiridina ; procedimiento de preparacion de estos; composicion framaceutica que los comprende; y su uso en el tratamiento de enfermedades cardiovasculares, sexuales y metabolicas.
DOP2014000115A (es) Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1
UA107783C2 (en) Isoindoline compounds for use in treating cancer
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
MX2013011922A (es) Compuestos de benceno substituido.
IN2014DN06501A (es)
SV2009003307A (es) Quinazolinas para la inhibicion de pdk1
BR112014000792A2 (pt) compostos de piperidinila para uso como inibidores da tanquirase
UY32937A (es) Compuestos y composiciones como moduladores de la actividad de gpr119
CL2011002548A1 (es) Compuestos derivados de resolviina; composicion farmaceutica; uso de la composicion; kit farmaceutico; combinacion farmaceutica; uso de los compuestos en el tratamiento y/o prevencion de una condicion oftalmica.
CL2013002003A1 (es) Compuestos derivados de 1, 2, 4-triazolo [4,3-a] quinoxalina, inhibidores de pde2 y/o 10; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para en el trastamiento de enfermedades del snc
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.
CL2015000039A1 (es) Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis.
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
CL2015000886A1 (es) Compuestos derivados de azaindolinas sustituidas, inhibidores de la union de proteinas smac al inhibidor de proteinas de apoptosis (iap) y/o inhibidores de la union de proteina caspasa activada a los iap; composicion farmaceutica que los comprende; metodo para tratar o mejorar un cancer; y su uso para el tratamiento terapeutico y/o profilactico del cancer.
CO2019009020A2 (es) Derivados de pirazol como inhibidores de bromodominio.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20190121